Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here we investigated the ability of magnetic resonance spectroscopy (MRS) to detect 2-HG production in order to non-invasively identify patients with IDH1 mutant brain tumors.
|
22015945 |
2012 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions.
|
23111198 |
2012 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The new 2016 WHO brain tumor classification defines different diffuse gliomas primarily according to the presence or absence of IDH mutations ( IDH-mt) and combined 1p/19q loss.
|
28640702 |
2017 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
|
20160062 |
2010 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here, we describe the isolation of a glioma brain tumor stem cell line (BT142) with an endogenous R132H mutation in IDH1, aggressive tumor-initiating capacity, and 2-HG production.
|
22166263 |
2012 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients.
|
22427879 |
2012 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To address this, we analyzed IDH1(R132) and IDH2(R172) mutation status 53 metastatic brain tumors, including nine melanoma metastases.
|
20603105 |
2010 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This study demonstrates the feasibility, specificity, and selectivity of using MR detection and quantification of 2HG for the diagnosis and classification of IDH1/2 mutation-positive brain tumors.
|
22426639 |
2012 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Another mitochondrial and TCA cycle-related protein, isocitrate dehydrogenase 2 is, together with IDH1, frequently mutated in the brain tumour glioblastoma.
|
20304625 |
2010 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Isocitrate Dehydrogenase-1 (<i>IDH1)</i> is a driver gene in several cancers including brain tumors such as low-grade and high-grade gliomas.
|
29971034 |
2018 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 (IDH1) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown.
|
19359588 |
2009 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study, we address this need by presenting a proton magnetic resonance spectroscopy ((1)H-MRS) acquisition scheme that uses an ultrahigh magnetic field (≥ 7T) capable of noninvasively detecting 2-HG with quantitative measurements sufficient to differentiate mutant cytosolic IDH1 and mitochondrial IDH2 in human brain tumors.
|
26669865 |
2016 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We also used targeted genotyping to examine the role of tumor-related genes in brain tumor development and specifically examined the clinical consequences of MAE at TP53 and IDH1.
|
22144470 |
2012 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
There is growing interest in identification of diagnostic, prognostic or predictive blood biomarkers in CNS tumor patients, and emerging studies indicate that certain brain tumors are indeed associated with distinct profiles of circulating factors such as proteins (e.g., glial fibrillary acidic protein), DNA fragments (e.g., containing mutated IDH) or miRNAs (e.g., miRNA-21).
|
23547822 |
2013 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Recently, aberrant methylation of MLH1, MGMT and MSI were shown to be associated with mutations in genes such as BRAF, RAS and IDH1 in colon and brain tumours.
|
23414134 |
2013 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as the most common initiating event for secondary glioblastoma, a brain tumor type arising with high frequency in the frontal lobe.
|
25225364 |
2014 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Exon 4 of IDH1 and IDH2 was analyzed in a series of brain tumors classified according to current WHO criteria.
|
29535392 |
2018 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
|
21069360 |
2011 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
|
18985363 |
2008 |
Brain Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Patients with wild-type IDH1 brain tumors and high podoplanin expression had a significantly increased VTE risk compared with those with mutant IDH1 tumors and no podoplanin expression (6-month risk 18.2% vs. 0%).
|
29676036 |
2018 |
Brain Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We used human glioma tissues and derived brain tumor stem cells (BTSCs) to study the expression of HIF1α target genes in IDH mutant ((mt)) and IDH wild-type ((wt)) tumors.
|
24366912 |
2014 |
Brain Neoplasms
|
0.500 |
CausalMutation
|
group |
CGI |
|
|
|